What are the Historical Developments and Current Growth Metrics of the Point-of-Care Glucose Testing Market?
The point-of-care glucose testing market has seen considerable growth due to a variety of factors.
•Over the past few years, the market size for point-of-care glucose testing has seen consistent growth. The market which was valued at $4.91 billion in 2024, is projected to increase to $5.15 billion in 2025 at a Compound Annual Growth Rate (CAGR) of 4.9%.
The historical growth is primarily due to the escalating cases of diabetes, enhanced understanding of diabetes management, the growing aged population, the upsurge in healthcare infrastructure and the acceptance of point-of-care testing.
What Does Future Hold for The Point-of-Care Glucose Testing Market Size?
The point-of-care glucose testing market is expected to maintain its strong growth trajectory in upcoming years.
• Expected to witness robust growth in the forthcoming years, the point-of-care glucose testing market is projected to escalate to $6.51 billion by 2029, registering a compound annual growth rate (CAGR) of 6.0%.
This predicted growth during the forecast period can be ascribed to a number of factors such as the rise in telemedicine services, increasing focus on personalized diabetes treatment, proliferation of diabetes management programs, heightened investment in research and development pertaining to glucose testing and the adoption of continuous glucose monitoring. Key trends forecasted for this period involve advancements in wearable glucose monitoring devices, inclusion of smartphone connectivity features into glucose testing, increasing prominence of point-of-care testing within home healthcare environments, utilization of artificial intelligence for analysing glucose data and the broadened scope of remote patient monitoring for diabetes.
What Are The Key Drivers Fueling Growth In The Point-of-Care Glucose Testing Market?
The increase in cases of diabetes is anticipated to fuel the expansion of the point-of-care glucose testing market. Diabetes, a chronic metabolic disease, causes a rise in blood sugar levels, which in the long run, results in serious harm to the heart, blood vessels, eyes, kidneys, and nerves. Point-of-care glucose testing is an often-utilised method for checking glucose levels in patients in hospitals, helping make swift treatment choices in reaction to changes in glucose levels and improving diabetes management and treatment outcomes. As an illustration, The National Health Service (NHS England), a publicly funded healthcare system in the UK, reported in June 2024 that the number of people recognized as having pre-diabetes by the NHS in England grew to 3,615,330 in 2023, an 18% rise from 3,065,825 in 2022. Furthermore, cases among those under 40 saw an almost 25% increase, escalating from 173,166 in 2022 to 216,440 in 2023. Hence, the rising occurrences of diabetes are spurring the growth of the point-of-care glucose testing market.
What Are The Principal Market Segments In The Global Point-of-Care Glucose Testing Industry?
The point-of-care glucose testing market covered in this report is segmented –
1) By Product: Lancet And Lancing Devices, Strips, Meters
2) By Testing Site: Fingertips, Alternate Site Testing
3) By Applications: Type-1 Diabetes, Type-2 Diabetes
4) By End-User: Professional Diagnostic Centers, Hospitals And Clinics, Home Care Settings, Other End Users
Subsegments:
1) By Lancet And Lancing Devices: Single-Use Lancets, Multi-Use Lancets, Adjustable Lancing Devices
2) By Strips: Glucose Test Strips, Ketone Test Strips, Combo Strips (Glucose And Ketone)
3) By Meters: Blood Glucose Meters, Continuous Glucose Monitoring (CGM) Meters, Bluetooth-Enabled Meters
Pre-Book The Point-of-Care Glucose Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Point-of-Care Glucose Testing Sector?
Product innovation is emerging as a leading trend in the point-of-care glucose testing market, as key players strive to develop novel products to bolster their market positioning. An example of this was in January 2022 when F. Hoffmann-La Roche AG, a Swiss healthcare firm, launched the Cobas Pulse, a fresh point-of-care blood glucose monitoring device for healthcare professionals. The product includes a companion gadget resembling a smartphone with its applications. The hand-held Cobas Pulse, equipped with an automatic glucose test strip reader, camera, and touchscreen, facilitates the recording of diagnostic data. Plus, its robust casing allows for disinfection and usage across all patient demographics, including neonates and intensive care patients. The device further enhances physicians' work processes by integrating the Glucommander dosage software into the blood glucose reader and offering downloadable decision-support applications from companies like Smart4Diagnostics, CardioSignal, and SteadySense.
Who Are the Key Players in the Point-of-Care Glucose Testing Market?
Major companies operating in the point-of-care glucose testing market include:
• F Hoffmann-La Roche Ltd.
• Abbott Laboratories Inc.
• Danaher Corporation
• Siemens Healthineers
• Becton
• Dickinson and Company
• TaiDoc Technology Corporation
• B. Braun Melsungen AG
• Beckman Coulter Inc.
• Nipro Corporation
• Dexcom Inc.
• Bio-Rad Laboratories Inc.
• LifeScan Inc.
• Nova Biomedical Corporation
• Ypsomed AG
• Ascensia Diabetes Care Holdings AG
• Trividia Health Inc.
• Radiometer Medical ApS
• HemoCue AB
• EKF Diagnostics Holdings plc
• Trinity Biotech plc
• Bionime Corporation
• PTS Diagnostics
• ForaCare Inc.
• Menarini Diagnostics
• ACON Laboratories Inc.
• Senseonics Holdings Inc.
• Prodigy Diabetes Care LLC
• Nemaura Medical Inc.
What are the Regional Insights into the Point-of-Care Glucose Testing Market?
North America was the largest region in the point-of-care glucose testing market in 2024. The regions covered in the point-of-care glucose testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
